Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform
Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform
The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage
该消息突出表明,迫切需要在早期阶段对这种疾病进行更一致、更大规模的检测
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") is pleased to note Eli Lilly & Co.'s results for its experimental drug for Alzheimer's disease, which demonstrated slowing the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. The drug, donanemab, slowed the disease by 35% over a year and a half in a trial of 1,182 patients with early-stage Alzheimer's. The results represent the second time Alzheimer's was slowed in a final-stage trial by a drug that clears a brain protein called amyloid.
不列颠哥伦比亚省温哥华--(Newsfile Corp.-2023 年 5 月 9 日)- 认知神经科学有限公司 (CSE:CGN)(OTCQB:CGNSF)(FSE:1UB) (“公司” 或 “认知度”) 很高兴地注意到 Eli Lilly & Co. '其治疗阿尔茨海默氏病的实验药物的结果表明,该药物在最后阶段的试验中减缓了该疾病的进展,为该公司申请美国批准铺平了道路。在一项针对1,182名早期阿尔茨海默氏症患者的试验中,这种名为donanemab的药物在一年半的时间内使这种疾病减缓了35%。这些结果是阿尔茨海默氏症在最后阶段的试验中第二次被一种能清除一种叫做淀粉样蛋白的药物减缓。
The success means patients and their caregivers could soon have another therapy shown to slow the disease alongside Eisai Co.'s Leqembi, which was approved in January. This announcement aligns with an ongoing successful clinical deployment of CognICA Platform in monitoring Cognitive Performance in Alzheimer's patients receiving disease-modifying therapy targeting beta amyloid.
Lilly's donanemab trial also looked at a population of 552 patients who were deemed to be at a greater level of disease severity based on brain scans. When that group was combined with the larger, less acute population, the drug showed less impressive results, slowing the progress of the disease by 22% over 18 months. This further highlights the vital importance of early detection and diagnosis, another huge unmet need when it comes to tackling Alzheimer's disease. According to the World Health Organization (WHO), the number of people with Alzheimer's disease and other forms of dementia who are not diagnosed is a significant concern. In fact, WHO estimates that approximately 50% of people with dementia worldwide are not diagnosed or are not aware of their diagnosis, so are unable to benefit from treatment.
On the Lilly results, Dr Richard Oakley, Associate Director of Research at Alzheimer's Society, said: "Promisingly, the trial demonstrated a 40% slowing in decline of everyday activities such as driving, doing hobbies and managing finances. We need decisions as quickly as possible from the regulators. But that's not the end of the story - we can't end up in a situation where there are new drugs being approved but people can't get access to them early in their dementia journey when they work best - we need more accurate, earlier dementia diagnosis."
这一成功意味着患者及其护理人员很快就会有另一种疗法被证明可以与卫材公司一起减缓这种疾病。”s Leqembi,它在一月份获得批准。该公告与Cognica Platform在监测接受靶向β淀粉样蛋白的疾病改善疗法的阿尔茨海默氏症患者的认知表现方面正在进行的成功临床部署相吻合。
礼来公司的donanemab试验还调查了552名患者,根据脑部扫描,这些患者被认为疾病严重程度更高。当该组与人数较多、急性较低的人群合用时,该药物的效果不那么令人印象深刻,在18个月内使疾病的进展减缓了22%。这进一步凸显了早期发现和诊断的至关重要性,这是应对阿尔茨海默氏病的另一个巨大未得到满足的需求。根据世界卫生组织(WHO)的数据,未被诊断出患有阿尔茨海默氏病和其他形式的痴呆症的人数令人严重担忧。事实上,世卫组织估计,全世界约有50%的痴呆症患者没有被诊断出来或不知道自己的诊断,因此无法从治疗中受益。
关于礼来公司的结果,阿尔茨海默氏症协会研究副董事理查德·奥克利博士说:“令人鼓舞的是,该试验表明,驾驶、做爱好和管理财务等日常活动的下降速度减缓了40%。我们需要监管机构尽快做出决定。但这还不是故事的结局——我们不可能最终陷入有新药获得批准但人们无法在痴呆症之旅的早期获得这些药物的境地——我们需要更准确、更早的痴呆症诊断。”
This is an area in which Cognetivity's technology is proving to be a game changer. Through the agreement with MS&AD, the ability to screen for early cognitive decline at a large scale has for the first time become a reality, helping to ensure that early signs of disease are detected routinely, when people can be helped and are still functional.
事实证明,Cognetivity的技术在这个领域改变了游戏规则。通过与MS&AD的协议,大规模筛查早期认知能力下降的能力首次成为现实,这有助于确保常规发现疾病的早期迹象,同时人们可以得到帮助并保持功能。
Dr Sina Habibi, CEO of Cognetivity Neurosciences commented: "We are absolutely delighted to see these results as it gives hope to millions of people affected by this devastating disease." He added: "What this highlights even further is the urgent need for early detection of diseases like Alzheimer's to be scaled across the world, which is exactly what we are enabling with our agreement with MS&AD, a major health insurance provider in Japan, and which we hope to continue to roll out across the world."
Cognetivity Neurosciences首席执行官西娜·哈比比博士评论说:“我们非常高兴看到这些结果,因为它为数百万受这种毁灭性疾病影响的人带来了希望。”他补充说:“这进一步突出表明,迫切需要在全球范围内推广阿尔茨海默氏症等疾病的早期检测,这正是我们与日本主要健康保险提供商MS&AD达成协议所实现的,我们希望继续在全球范围内推广。”
About Cognetivity Neurosciences
关于 Cognetivity 神经科学
Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Cognetivity's CognICATM uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, United Kingdom, Europe, and the Middle East, with regulatory approval in other regions expected in 2023.
Cognetivity 是一家科技公司,开发了用于医疗、商业和消费环境的认知测试平台。康耐力的 CogniCaTM 使用人工智能和机器学习技术来测试大脑大面积区域的表现,以帮助检测认知功能障碍的早期迹象。Cognica目前已在美国、英国、欧洲和中东上市,预计将于2023年在其他地区获得监管部门的批准。
On behalf of the Board of Directors
代表董事会
"Sina Habibi"
Sina Habibi
“Sina Habibi”
Sina Habibi
Chief Executive Officer and Director
首席执行官兼董事
Forward-Looking Statements:
前瞻性陈述:
Certain statements contained in this news release, including those identified by the words "anticipate," "assume," "believe," "plan," "estimate," "expect," "intend," "may," "should" and similar expressions, to the extent they relate to the Company or its management, constitute forward-looking information or statements (collectively, the "Forward-Looking Statements"). These forward-looking statements are not historical facts and reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions, and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on a number of assumptions regarding our current and future business strategies and the environment in which we operate. We assume no responsibility to update or revise forward-looking information to reflect new events or circumstances, except as required by law. Readers are cautioned not to place undue reliance on our forward-looking statements.
本新闻稿中包含的某些陈述,包括用 “预期”、“假设”、“相信”、“计划”、“估计”、“预期”、“打算”、“可能”、“应该” 等词语标识的陈述,以及与公司或其管理层相关的类似表述,构成前瞻性信息或陈述(统称为 “前瞻性陈述”)。这些前瞻性陈述不是历史事实,反映了当前对未来业绩或事件的预期。本新闻稿包含前瞻性陈述。这些前瞻性陈述不能保证未来的表现,涉及难以预测的风险、不确定性和假设。此类陈述基于当前的预期和各种估计、因素和假设,涉及已知和未知的风险、不确定性和其他因素。此类陈述和信息基于对我们当前和未来的业务战略以及我们运营环境的许多假设。除非法律要求,否则我们不负责更新或修改前瞻性信息以反映新的事件或情况。提醒读者不要过分依赖我们的前瞻性陈述。
The Canadian Securities Exchange is not responsible for the adequacy or accuracy of this release.
加拿大证券交易所对本新闻稿的充分性或准确性不承担任何责任。
For more information, please visit: website: or contact: info@cognetivity.com; media inquiries can be sent to pr@cognetivity.com.
欲了解更多信息,请访问: 网站:或联系方式:info@cognetivity.com;媒体咨询可以发送至 pr@cognetivity.com。
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问